Engineered nanoparticles for imaging and targeted drug delivery in hepatocellular carcinoma

被引：0
作者：
Xianzhe Yu [1 ]
Qin Zhang [2 ]
Leibo Wang [3 ]
Yan Zhang [4 ]
Lingling Zhu [1 ]
机构：
[1] Department of Medical Oncology, Cancer Center & Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Sichuan, Chengdu
[2] Department of Gastrointestinal Surgery, Chengdu Second People’s Hospital, No. 10 Qinyun Nan Street, Sichuan, Chengdu
[3] Department of Postgraduate Students, West China School of Medicine/West China Hospital, Sichuan University, Sichuan, Chengdu
[4] Department of Surgery, Beijing Jishuitan Hospital Guizhou Hospital Guiyang, Guizhou, Guiyang
来源：
Experimental Hematology & Oncology | / 14卷 / 1期
基金：
中国国家自然科学基金;
关键词：
Drug delivery; Early diagnosis; Hepatocellular carcinoma; Nanomedicine; Nanoparticles; Tumor imaging;
D O I：
10.1186/s40164-025-00658-z
中图分类号：
学科分类号：
摘要：
Liver cancer, notably hepatocellular carcinoma (HCC), poses a significant global health burden due to its high fatality rates. Conventional antitumor medications face challenges, including poor targeting, high toxicity, and drug resistance, leading to suboptimal clinical outcomes. This review focused on nanoparticle use in diagnosing and delivering medication for HCC, aiming to advance the development of nanomedicines for improved treatment outcomes. As an emerging frontier science and technology, nanotechnology has shown great potential, especially in precision medicine and personalized treatment. The success of nanosystems is attributable to their smaller size, biocompatibility, selective tumor accumulation, and lower toxicity. Nanoparticles, as a central part of nanotechnology innovation, have emerged in the field of medical diagnostics and therapeutics to overcome the various limitations of conventional chemotherapy, thus offering promising applications for improved selectivity, earlier and more precise diagnosis of cancers, personalized treatment, and overcoming drug resistance. Nanoparticles play a crucial role in drug delivery and imaging of HCC, with the body acting as a delivery system to target and deliver drugs or diagnostic reagents to specific organs or tissues, helping to accurately diagnose and target therapies while minimizing damage to healthy tissues. They protect drugs from early degradation and increase their biological half-life. © The Author(s) 2025.
引用
收藏
相关论文
共 169 条
  • [1] Sung H., Ferlay J., Siegel R.L., Et al., Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, pp. 209-249, (2021)
  • [2] Llovet J.M., Kelley R.K., Villanueva A., Et al., Hepatocellular carcinoma, Nat Rev Dis Primers, 7, (2021)
  • [3] Bent E.H., Wehrenberg-Klee E., Koay E.J., Goyal L., Wo J.Y., Integration of systemic and liver-directed therapies for locally advanced hepatocellular cancer: harnessing potential synergy for new therapeutic horizons, J Natl Compr Canc Netw, 19, pp. 567-576, (2021)
  • [4] Narayan R., Nayak U.Y., Raichur A.M., Garg S., Mesoporous silica nanoparticles: a comprehensive review on synthesis and recent advances, Pharmaceutics, 10, (2018)
  • [5] Xu M., Han X., Xiong H., Et al., Cancer nanomedicine: emerging strategies and therapeutic potentials, Molecules, 28, (2023)
  • [6] Mohajer F., Mirhosseini-Eshkevari B., Ahmadi S., Et al., Advanced nanosystems for cancer therapeutics: a review, ACS Appl Nano Mater, 6, pp. 7123-7149, (2023)
  • [7] Roma-Rodrigues C., Pombo I., Raposo L., Pedrosa P., Fernandes A.R., Baptista P.V., Nanotheranostics targeting the tumor microenvironment, Front Bioeng Biotechnol, 7, (2019)
  • [8] Chen F., Hong H., Zhang Y., Et al., In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles, ACS Nano, 7, pp. 9027-9039, (2013)
  • [9] Paranthaman S., Hani U., Osmani R.A.M., Bhosale R.R., Haider N., Current advances in nanoparticle-based approaches for the hepatocellular carcinoma treatment, Clin Res Hepatol Gastroenterol, 49, (2025)
  • [10] Vitale A., Cabibbo G., Iavarone M., Et al., Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept, Lancet Oncol, 24, pp. e312-e322, (2023)
12345678910